Ro07-3953
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H91ClF2N2O |
Molar mass | 389.35 g·mol−1 |
3D model (JSmol) | |
| |
|
Ro07-3953 (Diflunordazepam) is a benzodiazepine derivative which is the 2',6'-difluoro derivative of nordazepam. It was invented in the 1970s but was never marketed,[1][2] however it has recently appeared on the market as a designer drug, first reported in Sweden in December 2024.[3][4]
See also
[edit]References
[edit]- ^ Maddalena DJ, Johnston GA (February 1995). "Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks". Journal of Medicinal Chemistry. 38 (4): 715–724. doi:10.1021/jm00004a017. PMID 7861419.
- ^ So SS, Karplus M (December 1996). "Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors". Journal of Medicinal Chemistry. 39 (26): 5246–5256. doi:10.1021/jm960536o. PMID 8978853.
- ^ "EU Early Warning System – Formal Notification: EU‑EWS‑RCS‑FN‑2024‑0044 (Ro 07‑3953)" (PDF). EU Early Warning System (EWS) / EUDA. 16 December 2024.
- ^ "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.